---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-068564"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T22:56:08.941378+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Agenus Q1 net loss $26.4M ($1.03/sh); cash burn reduced; BOT/BAL 100% pCR in dMMR CRC

## Summary
- Q1 2025 cash $18.5M (down from $40.4M Dec 2024); operating cash burn $25.6M vs $38.2M YoY.
- Net loss $26.4M ($1.03/sh) narrowed from $63.5M ($3.04/sh) Q1 2024; revenue $24.1M (non-cash royalty).
- On track to cut annualized cash burn below $50M in H2 2025; final stages of collaboration for cash infusion.
- BOT/BAL showed 100% pCR in dMMR CRC at higher dose; NEOASIS study responses in TNBC, sarcomas; HCC durable.
- Appointed Dr. Richard Goldberg as Chief Development Officer to lead BOT/BAL regulatory engagement.

## SEC filing metadata
- accession: 0000950170-25-068564
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000095017025068564/0000950170-25-068564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000095017025068564/agen-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-068564
- JSON: https://secwatch.observer/filing/0000950170-25-068564.json
- Plain text: https://secwatch.observer/filing/0000950170-25-068564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.